ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2020
Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 28 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Integrated Biological Markers for the Prediction of Treatment Response in Depression
Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)
Who cites it
28 citing papers in PubMed, 5 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Examining the relationship between pre-treatment anhedonia and treatment outcomes in individuals with anxiety or depression: A systematic review.Journal of affective disorders · 2026Pooled it
- Effects of the selective serotonin reuptake inhibitors citalopram and escitalopram on glucolipid metabolism: a systematic review.Frontiers in endocrinology · 2025Pooled it
- The Role of the Serotonergic System in Time Perception: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Neural substrates of reward anticipation and outcome in schizophrenia: a meta-analysis of fMRI findings in the monetary incentive delay task.Translational psychiatry · 2022Pooled it
- Disrupted reward processing in Parkinson's disease and its relationship with dopamine state and neuropsychiatric syndromes: a systematic review and meta-analysis.Journal of neurology, neurosurgery, and psychiatry · 2022Pooled it
- Neuronally-enriched exosomal microRNA-27b mediates acute effects of ibuprofen on reward-related brain activity in healthy adults: a randomized, placebo-controlled, double-blind trial.Scientific reports · 2022Trial
- Acute Neurofunctional Effects of Escitalopram in Pediatric Anxiety: A Double-Blind, Placebo-Controlled Trial.Journal of the American Academy of Child and Adolescent Psychiatry · 2021Trial
- Interest-activity symptom severity predicts response to ketamine infusion in treatment-resistant depression.Psychopharmacology · 2021Trial
- Development of a baseline battery to optimize depression treatment assignment in primary care: Balancing breadth and brevity.Journal of affective disorders · 2026Article
- Developing Clinically Interpretable Neuroimaging Biotypes in Psychiatry.Biological psychiatry · 2026Review
- Patient perspectives on the challenges, obstacles, and opportunities in discussing and managing anhedonia in major depressive disorder (MDD): a focus group study.Annals of general psychiatry · 2026Article
- The association between anhedonia and prefrontal cortex activation in patients with major depression: a functional near-infrared spectroscopy study.European archives of psychiatry and clinical neuroscience · 2026Article
- Efficacy of Adjunctive Lumateperone 42 mg on Anhedonia and Across a Broad Range of Depressive Symptoms in Major Depressive Disorder: Post Hoc Analysis of a Phase 3, Randomized, Placebo-Controlled Trial.Neuropsychiatric disease and treatment · 2026Article
- From Neural Circuits to Behavior: Examining the Central Role of Anhedonia in Major Depression.Advances in experimental medicine and biology · 2026Review
- Which aspects of anhedonia predict response to pharmacotherapy in major depressive disorder?Psychological medicine · 2025Article
- From Rhythm to Relief: Heart Rate Variability as a Window into Anhedonia Response During Agomelatine Treatment in Major Depressive Disorder.Medicina (Kaunas, Lithuania) · 2025Article
- Beyond the serotonin deficit hypothesis: communicating a neuroplasticity framework of major depressive disorder.Molecular psychiatry · 2024Review
- Breakthroughs and challenges for generating brain network-based biomarkers of treatment response in depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Review
- Neuroimaging for precision medicine in psychiatry.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Review
- Brain Circuit-Derived Biotypes for Treatment Selection in Mood Disorders: A Critical Review and Illustration of a Functional Neuroimaging Tool for Clinical Translation.Biological psychiatry · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 15 institutions in 2 countries.
Funding
Abstract
Anhedonia is thought to reflect deficits in reward processing that are associated with abnormal activity in mesocorticolimbic brain regions. It is expressed clinically as a deficit in the interest or pleasure in daily activities. More severe anhedonia in major depressive disorder (MDD) is a negative predictor of antidepressant response. It is unknown, however, whether the pathophysiology of anhedonia represents a viable avenue for identifying biological markers of antidepressant treatment response. Therefore, this study aimed to examine the relationships between reward processing and response to antidepressant treatment using clinical, behavioral, and functional neuroimaging measures. Eighty-seven participants in the first Canadian Biomarker Integration Network in Depression (CAN-BIND-1) protocol received 8 weeks of open-label escitalopram. Clinical correlates of reward processing were assessed at baseline using validated scales to measure anhedonia, and a monetary incentive delay (MID) task during functional neuroimaging was completed at baseline and after 2 weeks of treatment. Response to escitalopram was associated with significantly lower self-reported deficits in reward processing at baseline. Activity during the reward anticipation, but not the reward consumption, phase of the MID task was correlated with clinical response to escitalopram at week 8. Early (baseline to week 2) increases in frontostriatal connectivity during reward anticipation significantly correlated with reduction in depressive symptoms after 8 weeks of treatment. Escitalopram response is associated with clinical and neuroimaging correlates of reward processing. These results represent an important contribution towards identifying and integrating biological, behavioral, and clinical correlates of treatment response. ClinicalTrials.gov: NCT01655706.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.